Phenylpiracetam
A phenylated racetam developed in Russia with more pronounced stimulant and physical-performance effects than piracetam. It is banned in competitive sport and its cognitive claims rest largely on limited Russian clinical literature and anecdote.
01 Overview
Phenylpiracetam (phenotropil) adds a phenyl group to piracetam, increasing lipophilicity and potency and giving it a distinctly stimulating character. It was developed in the Soviet/Russian space programme and is marketed as a medicine in Russia for a range of neurological indications.
Most supporting studies are Russian-language and small, covering stroke recovery, asthenia and cognitive complaints. It is prohibited by WADA as a stimulant, and users commonly report tolerance developing quickly with repeated use.
02 Mechanism
Racetam modulation of cholinergic and glutamatergic transmission plus effects on dopamine and NMDA signalling; the phenyl group adds psychostimulant-like activity.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Typical | 100–200 mg/day | Oral | Often used intermittently because tolerance builds quickly with daily use. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased alertness / stimulationNoticeable stimulant-like alertness; supported mainly by anecdote and small studies. | Moderate | Anecdotal | |
| Improved physical enduranceReputation for enhancing stamina and cold tolerance; basis for its sport ban. | Small-to-moderate | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Rapid toleranceEffects diminish quickly over consecutive days of use. | Mild | Common with daily use | Anecdotal | |
| InsomniaSleep disruption from the stimulating effect. | Mild | Common | Anecdotal |